| 21.06 14:56 | dpa-AFX: Health Canada Approves Takeda's HyQvia For Immunodeficiencies In Pediatric Patients |
| 21.06 14:05 | dpa-AFX: *TAKEDA CANADA GETS APPROVAL FOR HYQVIA AS PRIMARY & SECONDARY IMMUNODEFICIENCY REPLACEMENT THERAPY IN PEDIATRIC PATIENTS |
| 18.06 15:17 | dpa-AFX: Takeda Presents Long-Term Data From Phase 3 ADVANCE-CIDP 3 Trial Of HYQVIA In CIDP Patients |
| 18.06 14:06 | dpa-AFX: *TAKEDA REPORTS POSITIVE LONG-TERM RESULTS FOR HYQVIA IN CIDP MAINTENANCE TREATMENT |
| 17.06 15:29 | dpa-AFX: *OVID THERAPEUTICS REPORTS ON TAKEDA'S ANNOUNCEMENT OF PHASE 3 NEGATIVE RESULTS FOR SOTICLESTAT |
| 14.06 14:43 | dpa-AFX: Takeda Signs Option Agreement With Ascentage For Exclusive License For Olverembatinib |
| 14.06 14:06 | dpa-AFX: *TAKEDA SECURES EXCLUSIVE GLOBAL LICENSE OPTION FOR OLVEREMBATINIB FROM ASCENTAGE PHARMA |
| 07.06 05:12 | dpa-AFX: Former Takeda Employee Pleads Guilty To $2.3 Mln Embezzlement Scheme |
| 31.05 18:58 | dpa-AFX: Takeda Gets Positive CHMP Feedback For Recombinant ADAMTS13 |
| 31.05 17:23 | dpa-AFX: *TAKEDA GETS POSITIVE CHMP OPINION FOR RECOMBINANT ADAMTS13 |
| 16.05 16:42 | dpa-AFX: Takeda Canada Finalises LoI With PCPA For Antiviral Drug Livtencity |
| 16.05 14:07 | dpa-AFX: *TAKEDA CANADA CONCLUDES LOI WITH PCPA FOR LIVTENCITY IN ADULT POST-TRANSPLANT CMV TREATMENT |
| 13.05 12:36 | dpa-AFX: Takeda, AC Immune Sign License Agreement For Active Immunotherapy For Alzheimer's Disease |
| 13.05 12:05 | dpa-AFX: *AC IMMUNE, TAKEDA SIGN LICENSE AGREEMENT FOR ACTIVE IMMUNOTHERAPY TARGETING AMYLOID BETA FOR ALZHEIMER'S DISEASE |
| 09.05 09:20 | dpa-AFX: Takeda Full-year Profit Declines, But Revenue Ascends |
| 09.05 08:28 | dpa-AFX: *TAKEDA PHARMA FY CORE OPERATING PROFIT 1.188 TRLN YEN VS. 1.054 TRLN YEN LAST YEAR |
| 09.05 08:28 | dpa-AFX: *TAKEDA PHARMA FY NET INCOME 317.04 BLN YEN VS. 144.20 BLN YEN LAST YEAR |
| 09.05 08:28 | dpa-AFX: *TAKEDA PHARMA FY PRE-TAX INCOME 375.09 BLN YEN VS. 52.79 BLN YEN LAST YEAR |
| 09.05 08:28 | dpa-AFX: *TAKEDA PHARMA FY OPERATING PROFIT 490.51 BLN YEN VS. 214.08 BLN YEN LAST YEAR |
| 09.05 08:28 | dpa-AFX: *TAKEDA PHARMA FY REVENUE 4.027 TRLN YEN VS. 4.263 TRLN YEN LAST YEAR |
|
|
